Robin Joyce

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas et al. · Journal of Clinical Oncology · 2002 · 1.2K citations

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

John Koreth, Ken‐ichi Matsuoka, Haesook T. Kim et al. · New England Journal of Medicine · 2011 · 1.1K citations · Full text

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Paul G. Richardson, Edie Weller, Sagar Lonial et al. · Blood · 2010 · 855 citations · Full text

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

Jacalyn Rosenblatt, Brett Glotzbecker, Heidi Mills et al. · Journal of Immunotherapy · 2011 · 282 citations

Active Myeloma, Pd-1 Blockade, Immunology +19

Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma

Brad S. Kahl, Nancy L. Bartlett, John P. Leonard et al. · Cancer · 2009 · 245 citations · Full text